HealthCap VII Amends Carisma Therapeutics Stake
Ticker: CARM · Form: SC 13D/A · Filed: May 28, 2024 · CIK: 1485003
Sentiment: neutral
Topics: schedule-13d, beneficial-ownership, amendment
TL;DR
HealthCap VII filed an update on their Carisma Therapeutics stake. Watch this space.
AI Summary
HealthCap VII, L.P. filed an amendment (No. 3) to its Schedule 13D on May 28, 2024, regarding its beneficial ownership of Carisma Therapeutics Inc. The filing indicates a change in the reporting person's holdings, though specific new percentages or dollar amounts are not detailed in this excerpt. HealthCap VII, L.P. is a limited partnership based in Delaware, and Carisma Therapeutics Inc. is a pharmaceutical preparations company incorporated in Pennsylvania.
Why It Matters
This filing signals a potential shift in major shareholder activity for Carisma Therapeutics, which could influence stock price and corporate strategy.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership by significant holders can indicate shifts in strategy or market sentiment, impacting the company's stock.
Key Players & Entities
- HealthCap VII, L.P. (company) — Reporting Person
- Carisma Therapeutics Inc. (company) — Subject Company
- HealthCap VI GP S.A. (company) — Representative for HealthCap VII, L.P.
FAQ
What specific changes in beneficial ownership are reported in this amendment?
The filing is an amendment (No. 3) to Schedule 13D, indicating a change in reporting person's holdings, but the specific details of the change (e.g., number of shares, percentage) are not provided in this excerpt.
When was this amendment filed?
This amendment was filed on May 28, 2024.
Who is the subject company?
The subject company is Carisma Therapeutics Inc.
Who is the reporting person filing this amendment?
The reporting person is HealthCap VII, L.P., represented by HealthCap VI GP S.A.
What is the business address of Carisma Therapeutics Inc.?
The business address is 3675 Market Street, Suite 200, Philadelphia, PA 19104.
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-05-28 19:39:56
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
Filing Documents
- d812187dsc13da.htm (SC 13D/A) — 40KB
- 0001193125-24-148302.txt ( ) — 42KB
of the Schedule 13D is hereby amended and supplemented as follows
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Representatives of HealthCap VII Advisor AB, the advisor of the Reporting Persons, have, together with representatives of the Reporting Persons, engaged, and may continue to engage, with the Issuers management team regarding whether the Issuer should consider financing options, and if so, the timing and potential structure of such financing options, including, but not limited to, sales of the Issuers equity securities. Item5. Interest in Securities of the Issuer
of the Schedule 13d is hereby amended and supplemented as follows
Item 5 of the Schedule 13d is hereby amended and supplemented as follows: (a)-(b): The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on approximately 41,542,744 shares of Common Stock outstanding as of May 7, 2024, as reported in the Issuers Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024.
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this Dated: May 28, 2024 HEALTHCAP VII, L.P. By: HealthCap VII GP LLC, its general partner By: HealthCap VI GP SA, its investment manager By: /s/ Dag Richter Name: Dag Richter Title: Director By: /s/ Fabrice Bernhard Name: Fabrice Bernhard Title: General Manager HEALTHCAP VII GP LLC By: HealthCap VI GP SA, its investment manager By: /s/ Dag Richter Name: Dag Richter Title: Director By: /s/ Fabrice Bernhard Name: Fabrice Bernhard Title: General Manager